CD8A and neoplasm: Previous studies confirm that enrichment of CD4+ and CD8+ T cells and high expression of immune checkpoint genes in tumor tissues are generally associated with a good response to anti-PD-1/PD-L1 therapy (Chen and Mellman, 2017; Morad et al., 2021).